Pembrolizumab-Induced Hypophysitis With Isolated Adrenocorticotropic Hormone (ACTH) Deficiency: A Rare Immune-Mediated Adverse Event.
hypophysitis
immune checkpoint inhibitors (icis)
immune-related adverse event (irae)
pembrolizumab
programmed cell death protein 1
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
05 Jun 2021
05 Jun 2021
Historique:
entrez:
14
6
2021
pubmed:
15
6
2021
medline:
15
6
2021
Statut:
epublish
Résumé
Pembrolizumab is an immune checkpoint inhibitor that targets the programmed cell death protein 1 antigen to stimulate an immune response against tumor cells. It has successfully induced remission in patients with severe metastatic disease, including those refractory to other chemotherapeutic regimens. Immune checkpoint inhibitors may result in immune-related adverse events affecting multiple organs, including endocrine organs, leading to thyroiditis and hypophysitis, among others. Isolated adrenocorticotropic hormone deficiency and hypophysitis have been reported in patients treated with nivolumab, another programmed cell death protein 1 inhibitor. However, clinical characteristics of these side effects associated with pembrolizumab have yet to be described in detail. We describe a case of an 85-year-old Caucasian male undergoing treatment of metastatic urothelial carcinoma with pembrolizumab, who abruptly developed hypophysitis requiring emergent intervention.
Identifiants
pubmed: 34123679
doi: 10.7759/cureus.15465
pmc: PMC8186842
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e15465Informations de copyright
Copyright © 2021, Doodnauth et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Intern Med. 2019 Dec 15;58(24):3557-3562
pubmed: 31462588
Eur Heart J Case Rep. 2018 Apr 03;2(2):yty038
pubmed: 31020118
Case Rep Nephrol Dial. 2018 Aug 10;8(2):171-177
pubmed: 30197906
Eur J Endocrinol. 2019 Sep;181(3):211-219
pubmed: 31176301
Sci Transl Med. 2014 Apr 2;6(230):230ra45
pubmed: 24695685
Oncotarget. 2016 Nov 22;7(47):76565-76576
pubmed: 27655724
Sci Rep. 2019 Dec 19;9(1):19419
pubmed: 31857638